Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...
Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...
A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...
Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
Men with PAH had a larger right heart size and worse survival than women, independent of body size and functional status, a ...
Medicare beneficiaries with emphysema who received an endobronchial valve vs. lung volume reduction surgery faced elevated ...
In a world where respiratory issues are increasingly common, finding practical solutions can be daunting. Breathe Drops ...
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...
In today’s fast-paced world, respiratory issues have become increasingly common, affecting individuals of all ages. Whether it’s due to environmental pollutants, allergens, or chronic conditions like ...
As contemporary surgical practice continues to evolve, patients who undergo surgical lung volume reduction (LVRS) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback